Today we might glimpse the U.S. Food and Drug Administration’s thoughts on approving new type 2 diabetes drugs in a post-Avandia world. Nesina, a Takeda Pharmaceutical (TYO:4502) compound licensed from Furiex Pharmaceuticals (NASDAQ:FURX), is set for a prescription drug user fee act (PDUFA) decision today. The drug candidate, also known as alogliptin, was developed to […]
An investigational statin drug being developed by Furiex Pharmaceuticals (NASDAQ:FURX) has failed in phase 2 clinical trials, ending an attempt to produce what the company hoped would become an alternative to blockbuster Pfizer (NYSE:PFE) drug Lipitor. The compound PPD-10558 was being studied in patients with statin-associated myalgia, or SAM. This muscle pain can be one […]
A type 2 diabetes drug hopefully thought of as a potential blockbuster before stalling amid safety concerns is now taking another shot at approval. Takeda Pharmaceuticals (TYO:4502), which is partnered with Morrisville, North Carolina-based Furiex Pharmaceuticals (NASDAQ:FURX) on the diabetes drug candidate alogliptin, has filed two new drug applications for the compound with the U.S. […]
